Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2,474 JPY | +1.23% | -2.81% | +21.22% |
May. 27 | Olympus Enters into Put Option Agreement for Orthopedic Business Transfer | MT |
May. 13 | Olympus' Attributable Profit Soars 69.1% in Fiscal 2024 | MT |
Summary
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- The group's high margin levels account for strong profits.
- The company is in a robust financial situation considering its net cash and margin position.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- The opinion of analysts covering the stock has improved over the past four months.
Weaknesses
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- The company appears highly valued given the size of its balance sheet.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- Over the past twelve months, analysts' opinions have been revised negatively.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+21.22% | 18.34B | A- | ||
+7.01% | 217B | B | ||
+11.01% | 190B | B- | ||
+19.20% | 143B | B- | ||
+30.79% | 111B | A- | ||
+1.48% | 64.59B | A- | ||
+13.95% | 52.36B | B+ | ||
-0.16% | 48.45B | B+ | ||
-6.20% | 38.03B | A | ||
+0.91% | 35.6B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 7733 Stock
- Ratings Olympus Corporation